source
- RA Capital backs Oak Hill Bio's Nasdaq debut via $175 million SPAC mergerRA Capital announced that its SPAC, Research Alliance Corporation III, will merge with Oak Hill Bio, creating a new Nasdaq-listed rare-disease company. The combined entity will start with $175 mil…
- AstraZeneca says AI has yet to yield clinical candidates but could lower risk in late-stage trialsAstraZeneca's chief executive Pascal Soriot told reporters that the company's AI‑driven efforts in drug design have not yet produced a candidate that has entered clinical testing. He added that th…